Malik Fady Ibraham 4

What Happened

• Fady Ibraham, EVP Research & Development at Cytokinetics, reported sales of a total 12,033 shares on March 17, 2026. The sales were two transactions: 7,636 shares and 4,397 shares, each at $62.15 per share, yielding combined proceeds of approximately $747,851. These were sales (not purchases) and were company-compelled sell-to-cover transactions tied to RSU vesting.

Key Details

• Transaction dates and prices: 2026-03-17 — 7,636 shares @ $62.15 ($474,577) and 4,397 shares @ $62.15 ($273,274).
• Total shares sold: 12,033; total proceeds: ~$747,851.
• Shares owned after transaction: not specified in the filing.
• Footnotes: Both transactions are company-compelled sell-to-cover actions to satisfy tax withholding obligations attributable to RSU vesting (Footnotes F1 and F2).
• Filing timeliness: Filed 2026-03-18 for transactions on 2026-03-17 (no late filing indicated).

Context

• Sell-to-cover transactions are routine after restricted stock units (RSUs) vest: the company sells a portion of the vested shares to cover required tax withholding. Such transactions are typically administrative and do not necessarily signal the insider’s view of the company’s prospects.